Company Focus
Ipsen
Latest Ipsen News
Pharmaceutical
French drugmaker Ipsen today announced new data from two late-breaking presentations on Iqirvo (elafibranor) during the European Association for the Study of the Liver congress. 7 May 2025
Related News
Insights
Company Spotlight
A Swedish biotechnology company that specializes in the development of pharmaceuticals for various types of cancer and autoimmune/inflammatory diseases.
Latest News & Features of interest to Ipsen
Pharmaceutical
Shares in US healthcare conglomerate Johnson & Johnson rose by 6% during Wednesday morning’s trading after the presentation of its second-quarter financial results and latest guidance for 2025. 16 July 2025
Biotechnology
UK pharma major GSK is seeking US approval for Blenrep (belantamab mafodotin) in two multiple myeloma indications. 16 July 2025
Biotechnology
Canada and USA-based oncology biotech Repare Therapeutics has entered into an exclusive worldwide licensing agreement with privately-held Swiss firm Debiopharm International to establish tomorrow’s standards of care to cure cancer and infectious diseases, for lunresertib, a first-in-class precision oncology PKMYT1 inhibitor. 16 July 2025
Pharmaceutical
Alnylam has secured expanded UK regulatory approval for Amvuttra (vutrisiran), broadening its indication to include treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) in adults. 16 July 2025
Biotechnology
US pharma major AstraZeneca today released high-level results from the Cardiac Amyloid Reaching for Extended Survival (CARES) Phase III clinical program showed that anselamimab, a light chain depleter antibody, did not achieve statistical significance for the primary endpoint compared to placebo in patients with Mayo stages IIIa and IIIb light chain (AL) amyloidosis. 16 July 2025
Biotechnology
Japanese drugmaker JCR Pharmaceuticals has entered into a joint collaboration, option and license agreement with US biotech Acumen Pharmaceuticals to develop a novel therapeutic candidate for the treatment of Alzheimer’s disease (AD), enabled by JCR’s proprietary blood-brain barrier (BBB)-penetrating technology platform, J-Brain Cargo 16 July 2025
Biotechnology
The USA's Institute for Clinical and Economic Review (ICER) has released a Final Evidence Report assessing the comparative clinical effectiveness and value of Sanofi’s tolebrutinib for the treatment of secondary progressive multiple sclerosis (SPMS). 15 July 2025
Pharmaceutical
Russia will begin commercial production of a new anticancer vaccine, which massive supplies for the needs of domestic patients may begin already during the period of 2025-2026, reports The Pharma Letter’s local correspondent. 15 July 2025
Pharmaceutical
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has today approved Ekterly (sebetralstat) 0for the treatment of hereditary angioedema (HAE) attacks in adults and adolescents aged 12 years and older. 15 July 2025
Biotechnology
US biotech Tract Bio has appointed Chris Galloway as chief medical and development officer, as it prepares for an investigational new drug filing for its lead oncology candidate, TP-101, within the next 18 months. The Boston-based company is also expanding its board with two senior figures from the oncology and biotech world: Mark Adler and Kristiina Vuori. 15 July 2025
Latest In Brief for Ipsen
Pharmaceutical
Ireland-based biopharma Jazz Pharmaceuticals has been called out for a couple of indiscretions by The Prescription Medicines Code of Practice Authority (PMCPA), which was established by the Association of the British Pharmaceutical Industry (ABPI) to operate the ABPI Code of Practice for the Pharmaceutical Industry. 11 July 2025
Latest Relevant Ones To Watch News
US CAR-T focused biotech CARGO Therapeutics today announced that it has entered into a definitive merger agreement with Concentra Biosciences, initially worth roughly $200 million. The news sent CARGO’s stock up as much as 9.6% to $4.81 in pre-market activity. 12 July 2025
16 June 2025
12 June 2025
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze